Divis Laboratories gets EIR for Unit-II at Visakhapatnam
From USFDA
Divis Laboratories has received an Establishment Inspection Report (EIR) from US-FDA for the Company's Unit-II at Visakhapatnam, as closure of audit by FDA.The company's Unit-II at Visakhapatnam was inspected by US-FDA in September 2017 wherein a Form-483 was issued with 6 observations.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content